Retraction Note: Blockage of miR-92a-3p with locked nucleic acid induces apoptosis and prevents cell proliferation in human acute megakaryoblastic leukemia (Cancer Gene Therapy, (2016), 23, 1, (29-35), 10.1038/cgt.2015.63);Blockage of MIR-92a-3p with locked nucleic acid induces apoptosis and prevents cell proliferation in human acute megakaryoblastic leukemia

Cancer Gene Therapy

Volumn 23, Issue 1, 2016, Pages 29-35

  Sharifi, M ^a   Salehi, R ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 92A 3P; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN92 MICRORNA, HUMAN; OLIGONUCLEOTIDE;

ACUTE MEGAKARYOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MTT ASSAY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; METABOLISM; NECROSIS; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MICRORNAS; NECROSIS; OLIGONUCLEOTIDES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84954365686     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/s41417-019-0158-y     Document Type: Erratum

References (44)

1. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15: 509-524.
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854.
3. Drakaki A, Iliopoulos D. MicroRNA gene networks in oncogenesis. Curr Genomics 2009; 10: 35.
4. Taylor DD, Gercel-taylor C. MicroRNA biomarkers. In: US Patent 20150018227, 2015.
5. Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239-250.
6. Hussein K, Büsche G, Muth M, Göhring G, Kreipe H, Bock O. Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. Ann Hematol 2011; 90: 307-313.
7. Farazi T, Hoell J, Morozov P, Tuschl T. MicroRNAs in Human Cancer. In: Schmitz U, Wolkenhauer O, Vera J (eds). MicroRNA Cancer Regulation, vol. 774. Springer: The Netherlands, 2013, pp 1-20.
8. Geusens B, Strobbe T, Bracke S, Dynoodt P, Sanders N, Gele MV et al. Lipidmediated gene delivery to the skin. Eur J Pharm Sci 2011; 43: 199-211.
9. Wang H, Lu H, Yang W, Luo C, Lu S, Zhou Y et al. The influence of statin therapy on circulating microRNA-92a expression in patients with coronary heart disease. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2012; 24: 215.
10. Hammond SM. RNAi, microRNAs, and human disease. Cancer Chemother Pharmacol 2006; 58: 63-68.
11. Najafi Z, Sharifi M, Javadi G. Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma. Cancer Gene Ther 2015; 22: 530-535.
12. Klepin H, Pardee T. Acute Myeloid Leukemia. In: Wedding U, Audisio RA (eds). Management of Hematological Cancer in Older People. Springer: London, 2015, pp 63-83.
13. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. Acute Myeloid Leukemia. McGraw-Hill: New York, 2012.
14. Molina CA, Rodríguez MJR, de Marcos NS, Font P. Acute myeloblastic leukemia. Adv Ther 2011; 28: 10-16.
15. Hamdi FY, Hamdi MN, Hamadi AY, Algehainy NA, Mahzari AM. Role of Different MicroRNAs in Acute Myeloid Leukemia. Int J Genetics Cancer 2015; 1: 3-4.
16. Ranganathan P, Garzon R. Clinical Implications of MicroRNAs in AML. In: Andreeff M (ed). Targeted Therapy of Acute Myeloid Leukemia. Springer: New York, 2015, pp 699-705.
17. Zhu Y-D, Wang L, Sun C, Fan L, Zhu D-X, Fang C et al. Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia. Med Oncol 2012; 29: 2323-2331.
18. Benetatos L, Vartholomatos G. MicroRNAs mark in the MLL-rearranged leukemia. Ann Hematol 2013; 92: 1439-1450.
19. Kandi R, Undi R, Gutti RK. MiR-125b regulates cell proliferation and survival in neonatal megakaryocytes. Ann Hematol 2014; 93: 1065-1066.
20. Testa U, Pelosi E. MicroRNAs expressed in hematopoietic stem/progenitor cells are deregulated in acute myeloid leukemias. Leukemia & lymphoma 2015; 56: 1466-1474.
21. Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M et al. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes 2010; 3: 347.
22. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K et al. Downregulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009; 4: e5532.
23. Manni I, Artuso S, Careccia S, Rizzo MG, Baserga R, Piaggio G et al. The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J 2009; 23: 3957-3966.
24. Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A et al. The miR-17-92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci USA 2009; 106: 2812.
25. Yoshizawa S, Ohyashiki J, Ohyashiki M, Umezu T, Suzuki K, Inagaki A et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J 2012; 2: e53.
26. Braoudaki M, Lambrou GI. MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown. J Hematol Oncol 2015; 8: 6.
27. Ramzy I, Hasaballah M, Marzaban R, Shaker O, Soliman ZA. Evaluation of microRNAs-29a, 92a and 145 in colorectal carcinoma as candidate diagnostic markers: an Egyptian pilot study. Clin Res Hepatol Gastroenterol 2015; 39: 508-515.
28. Zhu L, Chen H, Zhou D, Li D, Bai R, Zheng S et al. MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med Oncol 2012; 29: 1037-1043.
29. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3: 1.
30. Ørom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006; 372: 137-141.
31. Stoffel M, Poy MN, Tuschl TH. MicroRNA and methods for inhibiting same. Google Patents, 2014.
32. Kadia T, Ravandi F. Induction Therapy in Acute Myeloid Leukemia. In: Cancer Consult: Expertise for Clinical Practice. John Wiley & Sons, Ltd, 2014, pp 58-66.
33. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159.
34. Cheng CJ, Engelman DM, Saltzman M, Slack FJ. Targeting the tumor microenvironment with antimiRs that exploit oncomiR addiction in lymphoma. Cancer Res 2014; 74: 974-974.
35. Sharifi M, Salehi R, Gheisari Y, Kazemi M. Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression. Mol Biol Rep 2014; 41: 2799-2808.
36. Zhou C, Shen L, Mao L, Wang B, Li Y, Yu H. miR-92a is upregulated in cervical cancer and promotes cell proliferation and invasion by targeting FBXW7. Biochem Biophys Res Commun 458: 63-692015.
37. Li M, Guan X, Sun Y, Mi J, Shu X, Liu F et al. miR-92a family and their target genes in tumorigenesis and metastasis. Exp Cell Res 2014; 323: 1-6.
38. Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S et al. Estrogen receptor β1 expression is regulated by miR-92 in breast cancer. Cancer Res 2010; 70: 4778.
39. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159.
40. Sharifi M, Salehi R, Gheisari Y, Kazemi M. Inhibition of MicroRNA miR-92a inhibits cell proliferation in human acute promyelocytic leukemia. Turk J Haematol 2013; 30: 157.
41. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Haematol 2009; 37: 649-658.
42. Gu J, Zhu X, Li Y, Dong D, Yao J, Lin C et al. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol 2011; 28: 211-218.
43. Li Y, Zhu X, Gu J, Dong D, Yao J, Lin C et al. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 2010; 101: 948-954.
44. Rashidi A, Fisher SI. Acute megakaryoblastic leukemia. Blood 2013; 122: 2537-2537.